HUGE ANNOUNCEMENT: Merck to buy Schering Plough.
Former reps accuse J&J unit of marketing Risperdal off-label. Johnson & Johnson’s Janssen Pharmaceutica unit pushed sales representatives to promote its antipsychotic drug Risperdal for uses not approved by regulators, three former salespeople said in a lawsuit against the company. J&J tried to promote Risperdal for conditions beyond schizophrenia, its approved use until December 2003, according to sworn statements among almost 1,000 pages of documents in the case in Trenton, New Jersey. To boost sales of the medicine, J&J urged doctors to prescribe Risperdal for conditions such as bipolar disorder and depression, the declarations say.
From Forbes: Creating new, innovative vaccines.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff